Evidence · Randomised trial
The bilirubin albumin ratio in the management of hyperbilirubinemia in preterm infants to improve neurodevelopmental outcome: a randomized controlled trial--BARTrial.
- Jaundice and haematology
- Jaundice and phototherapy
- Medical
- Neurodevelopmental follow-up
- Neurology
- Nursing
This paper is from 2014, more than five years ago. Newer evidence may have been published since.
Summary
This randomised controlled trial (BARTrial) enrolled 615 preterm infants of 32 weeks' gestation or less to compare management of hyperbilirubinaemia using bilirubin/albumin ratio plus total serum bilirubin thresholds against total serum bilirubin thresholds alone. The primary outcome was neurodevelopment at 18 to 24 months' corrected age using the Bayley-III, with secondary outcomes including complications of preterm birth and death. Motor and cognitive composite scores did not differ between groups, and adding the B/A ratio did not improve neurodevelopmental outcome. It informs phototherapy and exchange transfusion decision-making in very preterm infants.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.